{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T05:40:55Z","timestamp":1792734055136,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"7414","license":[{"start":{"date-parts":[[2012,7,22]],"date-time":"2012-07-22T00:00:00Z","timestamp":1342915200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1038\/nature11303","type":"journal-article","created":{"date-parts":[[2012,7,20]],"date-time":"2012-07-20T09:43:43Z","timestamp":1342777423000},"page":"155-159","source":"Crossref","is-referenced-by-count":354,"title":["Heterodimeric JAK\u2013STAT activation as a mechanism of persistence to JAK2 inhibitor therapy"],"prefix":"10.1038","volume":"489","author":[{"given":"Priya","family":"Koppikar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Bhagwat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Outi","family":"Kilpivaara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taghi","family":"Manshouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazhar","family":"Adli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Hricik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay M.","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Mullally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Abdel-Wahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abby","family":"Weinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachie","family":"Marubayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aviva","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mithat","family":"G\u00f6nen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeev","family":"Estrov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin L.","family":"Ebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Chiosis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Nimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley E.","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross L.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,7,22]]},"reference":[{"key":"BFnature11303_CR1","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C James","year":"2005","unstructured":"James, C. et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434, 1144\u20131148 (2005)","journal-title":"Nature"},{"key":"BFnature11303_CR2","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics, R. et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352, 1779\u20131790 (2005)","journal-title":"N. Engl. J. Med."},{"key":"BFnature11303_CR3","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter, E. J. et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365, 1054\u20131061 (2005)","journal-title":"Lancet"},{"key":"BFnature11303_CR4","doi-asserted-by":"publisher","first-page":"22788","DOI":"10.1074\/jbc.C500138200","volume":"280","author":"R Zhao","year":"2005","unstructured":"Zhao, R. et al. Identification of an acquired JAK2 mutation in polycythemia vera. J. Biol. Chem. 280, 22788\u201322792 (2005)","journal-title":"J. Biol. Chem."},{"key":"BFnature11303_CR5","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","volume":"3","author":"Y Pikman","year":"2006","unstructured":"Pikman, Y. et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 3, e270 (2006)","journal-title":"PLoS Med."},{"key":"BFnature11303_CR6","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","volume":"363","author":"S Verstovsek","year":"2010","unstructured":"Verstovsek, S. et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N. Engl. J. Med. 363, 1117\u20131127 (2010)","journal-title":"N. Engl. J. Med."},{"key":"BFnature11303_CR7","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1200\/JCO.2010.32.8021","volume":"29","author":"A Pardanani","year":"2011","unstructured":"Pardanani, A. et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J. Clin. Oncol. 29, 789\u2013796 (2011)","journal-title":"J. Clin. Oncol."},{"key":"BFnature11303_CR8","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker, B. J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031\u20131037 (2001)","journal-title":"N. Engl. J. Med."},{"key":"BFnature11303_CR9","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1002011","volume":"363","author":"KT Flaherty","year":"2010","unstructured":"Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809\u2013819 (2010)","journal-title":"N. Engl. J. Med."},{"key":"BFnature11303_CR10","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMoa0904554","volume":"361","author":"R Rosell","year":"2009","unstructured":"Rosell, R. et al. Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 361, 958\u2013967 (2009)","journal-title":"N. Engl. J. Med."},{"key":"BFnature11303_CR11","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok, T. S. et al. Gefitinib or carboplatin\u2013paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947\u2013957 (2009)","journal-title":"N. Engl. J. Med."},{"key":"BFnature11303_CR12","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1056\/NEJMoa044238","volume":"352","author":"S Kobayashi","year":"2005","unstructured":"Kobayashi, S. et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352, 786\u2013792 (2005)","journal-title":"N. Engl. J. Med."},{"key":"BFnature11303_CR13","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1371\/journal.pmed.0020073","volume":"2","author":"W Pao","year":"2005","unstructured":"Pao, W. et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2, e73 (2005)","journal-title":"PLoS Med."},{"key":"BFnature11303_CR14","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre, M. E. et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876\u2013880 (2001)","journal-title":"Science"},{"key":"BFnature11303_CR15","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1126\/science.1141478","volume":"316","author":"JA Engelman","year":"2007","unstructured":"Engelman, J. A. et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039\u20131043 (2007)","journal-title":"Science"},{"key":"BFnature11303_CR16","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1371\/journal.pmed.0020017","volume":"2","author":"W Pao","year":"2005","unstructured":"Pao, W. et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2, e17 (2005)","journal-title":"PLoS Med."},{"key":"BFnature11303_CR17","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/nature09627","volume":"468","author":"CM Johannessen","year":"2010","unstructured":"Johannessen, C. M. et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468, 968\u2013972 (2010)","journal-title":"Nature"},{"key":"BFnature11303_CR18","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/nature09626","volume":"468","author":"R Nazarian","year":"2010","unstructured":"Nazarian, R. et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973\u2013977 (2010)","journal-title":"Nature"},{"key":"BFnature11303_CR19","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/S0092-8674(03)00190-9","volume":"112","author":"M Azam","year":"2003","unstructured":"Azam, M., Latek, R. R. & Daley, G. Q. Mechanisms of autoinhibition and STI-571\/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112, 831\u2013843 (2003)","journal-title":"Cell"},{"key":"BFnature11303_CR20","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","volume":"2","author":"NP Shah","year":"2002","unstructured":"Shah, N. P. et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2, 117\u2013125 (2002)","journal-title":"Cancer Cell"},{"key":"BFnature11303_CR21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","volume":"141","author":"SV Sharma","year":"2010","unstructured":"Sharma, S. V. et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69\u201380 (2010)","journal-title":"Cell"},{"key":"BFnature11303_CR22","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0092-8674(00)81167-8","volume":"93","author":"E Parganas","year":"1998","unstructured":"Parganas, E. et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 93, 385\u2013395 (1998)","journal-title":"Cell"},{"key":"BFnature11303_CR23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.gde.2006.12.009","volume":"17","author":"JN Ihle","year":"2007","unstructured":"Ihle, J. N. & Gilliland, D. G. Jak2: normal function and role in hematopoietic disorders. Curr. Opin. Genet. Dev. 17, 8\u201314 (2007)","journal-title":"Curr. Opin. Genet. Dev."},{"key":"BFnature11303_CR24","doi-asserted-by":"publisher","first-page":"9414","DOI":"10.1073\/pnas.0811761106","volume":"106","author":"CG Mullighan","year":"2009","unstructured":"Mullighan, C. G. et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc. Natl Acad. Sci. USA 106, 9414\u20139418 (2009)","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature11303_CR25","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.1172\/JCI42442","volume":"120","author":"S Marubayashi","year":"2010","unstructured":"Marubayashi, S. et al. HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. J. Clin. Invest. 120, 3578\u20133593 (2010)","journal-title":"J. Clin. Invest."},{"key":"BFnature11303_CR26","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1182\/blood-2009-04-218842","volume":"115","author":"P Koppikar","year":"2010","unstructured":"Koppikar, P. et al. Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis. Blood 115, 2919\u20132927 (2010)","journal-title":"Blood"},{"key":"BFnature11303_CR27","doi-asserted-by":"publisher","first-page":"30985","DOI":"10.1074\/jbc.M701794200","volume":"282","author":"L Rider","year":"2007","unstructured":"Rider, L., Shatrova, A., Feener, E. P., Webb, L. & Diakonova, M. JAK2 tyrosine kinase phosphorylates PAK1 and regulates PAK1 activity and functions. J. Biol. Chem. 282, 30985\u201330996 (2007)","journal-title":"J. Biol. Chem."},{"key":"BFnature11303_CR28","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1158\/2159-8290.CD-11-0324","volume":"2","author":"R Andraos","year":"2012","unstructured":"Andraos, R. et al. Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent. Cancer Discov. 2, 512\u2013523 (2012)","journal-title":"Cancer Discov."},{"key":"BFnature11303_CR29","doi-asserted-by":"publisher","first-page":"5024","DOI":"10.1182\/blood-2009-05-222133","volume":"114","author":"Y Wang","year":"2009","unstructured":"Wang, Y. et al. Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood 114, 5024\u20135033 (2009)","journal-title":"Blood"},{"key":"BFnature11303_CR30","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/sj.leu.2405049","volume":"22","author":"V Guerini","year":"2007","unstructured":"Guerini, V. et al. The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2V617F. Leukemia 22, 740\u2013747 (2007)","journal-title":"Leukemia"},{"key":"BFnature11303_CR31","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1021\/jm0508078","volume":"49","author":"H He","year":"2006","unstructured":"He, H. et al. Identification of potent water-soluble purine-scaffold inhibitors of the heat shock protein 90. J. Med. Chem. 49, 381\u2013390 (2006)","journal-title":"J. Med. Chem."},{"key":"BFnature11303_CR32","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/nature06008","volume":"448","author":"TS Mikkelsen","year":"2007","unstructured":"Mikkelsen, T. S. et al. Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature 448, 553\u2013560 (2007)","journal-title":"Nature"}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nature11303.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nature11303","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nature11303.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T14:02:39Z","timestamp":1684418559000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nature11303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,22]]},"references-count":32,"journal-issue":{"issue":"7414","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["BFnature11303"],"URL":"https:\/\/doi.org\/10.1038\/nature11303","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,22]]}}}